4 things you missed from Day 4 of the Musk v. Altman trial, including testimony of Musk's money manager

Elon Musk returned to the witness stand in his civil trial against OpenAI and Sam Altman, with testimony also coming from Musk money manager Jared Birchall on $38 million in donations to OpenAI and related security arrangements. The judge curtailed Musk's repeated references to an AI "Terminator" scenario, keeping the case focused on the nonprofit-to-for-profit transition dispute. Next week, the jury is set to hear from OpenAI president Greg Brockman, whose diary entries are central evidence in the case.

Analysis

The near-term market read is less about the legal merits than about how the case reshapes bargaining power inside the AI ecosystem. A credible discovery record that questions OpenAI’s original funding/use restrictions could increase headline volatility for MSFT and GOOGL indirectly, because it raises the probability of more aggressive governance remedies, injunction requests, or settlement constraints on OpenAI’s operating flexibility. Even if the plaintiff does not win on the core claim, the process itself keeps a premium on caution around strategic AI partnerships, which tends to favor incumbents with broader internal AI stacks and less single-counterparty exposure.

For TSLA, the overhang is subtler: Musk’s testimony reinforces that his capital and attention are spread across too many strategic battles, and the market typically discounts that only after repeated reminders. The bigger second-order effect is on xAI’s ability to recruit, raise, and strike commercial agreements at attractive terms; if the market perceives xAI as litigation-adjacent or distraction-prone, counterparties may demand better economics or tighter indemnities. That is mildly negative for any business model that depends on rapid external deployment and partnership leverage.

The contrarian angle is that the market may be overestimating binary legal risk and underestimating duration risk. A trial like this can drag for months, but the price impact often comes from incremental revelations that alter narrative quality rather than verdict probability. If Brockman’s testimony is cleaner for OpenAI than the diary excerpts imply, the event could actually de-risk MSFT by reducing the odds of a broader governance reset; if it cuts the other way, the most exposed trade is not OpenAI directly but Microsoft’s option value on the ecosystem through strategic entanglement.

Key Decisions for Investors

• Keep a tactical underweight in MSFT for the next 2-6 weeks; the asymmetry is modest downside from governance/partnership headlines versus limited upside until witness sequence clears. Risk/reward improves if the stock sells off >3% on trial headlines without broader Nasdaq weakness.
• Maintain a small short TSLA vs long GOOGL pair into next week’s testimony. Thesis: TSLA carries ongoing key-man and distraction discount, while GOOGL benefits if AI governance scrutiny broadens to competitors with deeper balance-sheet capacity. Cover if TSLA outperforms by >5% on a clean legal week.
• Buy limited-risk downside in TSLA through event week, e.g. 1-2 month puts financed partially by selling farther OTM puts. The catalyst window is days-to-weeks, and the payoff is best if Musk-related testimony reintroduces management distraction risk.
• Use any OpenAI-related volatility to accumulate exposure to infrastructure beneficiaries rather than model winners; in public markets that favors MSFT only on pullbacks, but with a tighter stop because headline risk is still unresolved. Time horizon: 1-3 months.
• Avoid chasing a direct short on MSFT here; prefer waiting for a post-Brockman inflection. If testimony materially weakens OpenAI’s governance posture, consider adding to short-duration downside hedges instead of outright equity shorts.